Am J Hum Genet

1. CHENG S, Suger AH, Goss LB, Zhang J, et al
   Validation and context-dependent effects of a prostate cancer polygenic risk score in the All of Us Research Program.
   Am J Hum Genet. 2026;113:392-398.
   

   >> Share

   
   

   
   Anticancer Res

2. YAMADA Y, Shirafuji T, Sato K, Tsujino T, et al
   Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy.
   Anticancer Res. 2026;46:1107-1116.
   

   >> Share

   
   
3. LIU J, Hsu CY, Lu J, Zhang LE, et al
   Prognostic Significance of PPFIA2 in Localized Prostate Cancer: Integrative Analysis and Functional Validation.
   Anticancer Res. 2026;46:757-770.
   

   >> Share

   
   

   
   BMC Cancer

4. AVASTHI KK, Manley BJ, Pellini B, Zhang J, et al
   Different plasma exosome isolation methods generated distinct microRNA and protein profiles in healthy controls and patients with advanced prostate and lung cancer.
   BMC Cancer. 2025 Dec 30. doi: 10.1186/s12885-025-15492.
   

   >> Share

   
   

   
   BMC Urol

5. XU L, Wang J
   Multimodal management of primary mixed neuroendocrine prostate cancer with bone flare phenomenon: a rare case report and therapeutic insights.
   BMC Urol. 2026 Feb 5. doi: 10.1186/s12894-026-02064.
   

   >> Share

   
   
6. BEDIR S, Unal B, Ebiloglu T, Demiral S, et al
   The comparison of post-treatment quality of life after at least two years of follow-up (>/= 24 months) between robotic radical prostatectomy and radiotherapy for intermediate-risk localized prostate cancer.
   BMC Urol. 2026 Feb 5. doi: 10.1186/s12894-025-02018.
   

   >> Share

   
   
7. ALTAY MS, Kocaturk H, Bedir B, Bedir F, et al
   Impact of positive surgical margin location on biochemical recurrence in pT3 prostate cancer after robot-assisted radical prostatectomy: a retrospective cohort study.
   BMC Urol. 2026 Feb 4. doi: 10.1186/s12894-026-02069.
   

   >> Share

   
   

   
   Cancer

8. MONTGOMERY B, Lynch JA, Brown J, Maxwell KN, et al
   Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot study.
   Cancer. 2026;132:e70283.
   

   >> Share

   
   
9. LANE BR, Lewicki P, Noyes SL, Labardee C, et al
   Incidence and oncologic outcomes of patients with prostate-specific antigen persistence after radical prostatectomy.
   Cancer. 2026;132:e70291.
   

   >> Share

   
   

   
   Cancer Res

10. MONTEAGUDO-GARCIA O, Nombela P, Roman AC, Fernandez-Rodero V, et al
    ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation.
    Cancer Res. 2026;86:622-641.
    

    >> Share

    
    

    
    Clin Cancer Res

11. MUNZUR AD, Herberts C, Kwan EM, Emmett L, et al
    Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer.
    Clin Cancer Res. 2026 Feb 6. doi: 10.1158/1078-0432.CCR-25-4001.
    

    >> Share

    
    

    
    Eur Radiol

12. ENGLMAN C, Adebusoye B, Cosenza M, Del Prete A, et al
    Inter- and intra-rater variability of MRI-based lesion size measurements in active surveillance for prostate cancer: a multicentre study.
    Eur Radiol. 2026 Feb 6. doi: 10.1007/s00330-025-12318.
    

    >> Share

    
    
13. RENARD-PENNA R
    The velocity challenge: MRI reveals highly variable prostate cancer growth rates in active surveillance.
    Eur Radiol. 2026 Feb 6. doi: 10.1007/s00330-025-12312.
    

    >> Share

    
    

    
    Eur Urol

14. ARMSTRONG AJ, Petrylak DP, Shore ND, Szmulewitz RZ, et al
    ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients.
    Eur Urol. 2026 Feb 2:S0302-2838(25)04876-6. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    

    
    Hum Pathol

15. LANIPEKUN OK, Wang Y, Miyamoto H
    Clinical significance of the relative location of perineural cancer invasion on prostate biopsy: Detection within 1-mm of the core tip as an independent prognosticator.
    Hum Pathol. 2026;168:106015.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

16. HOWELL JN, Wilkes J, Maughan NM, Patel RB, et al
    Industry Sponsorship and Disease Site Focus in Therapeutic Radiopharmaceutical Clinical Trials Over the Past Decade.
    Int J Radiat Oncol Biol Phys. 2026;124:575-580.
    

    >> Share

    
    

    
    Int J Urol

17. UMEMORI M, Urabe F, Iwamoto Y, Imai Y, et al
    Impact of Immunohistochemical PSA and Ki-67 Expression on Prognosis in Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2026;33:e70368.
    

    >> Share

    
    
18. MIURA N, Shimbo M, Shishido K, Nobumori S, et al
    Impact of the 2025 NCCN Definition Change for Very High-Risk Prostate Cancer on Surgical Outcomes After Robot-Assisted Radical Prostatectomy: A Retrospective Cohort.
    Int J Urol. 2026;33:e70366.
    

    >> Share

    
    
19. SASAKI T, Igarashi A, Ebara S, Tatenuma T, et al
    Prognostic Factors of Castration-Resistant Prostate Cancer Among Patients With Localized Prostate Cancer Who Underwent Robot-Assisted Radical Prostatectomy in a Retrospective Multicenter Japanese Cohort (MSUG94).
    Int J Urol. 2026;33:e70370.
    

    >> Share

    
    
20. HATAKEYAMA S, Yoneyama T, Ohyama C
    Beyond Total PSA: Clinical Significance of S2,3PSA% in Reducing Unnecessary Prostate Biopsies.
    Int J Urol. 2026;33:e70371.
    

    >> Share

    
    

    
    J Natl Cancer Inst

21. FISCHER MP, Alena M, Braun A, Kraft J, et al
    Polygenic risk scores for pre-MRI risk stratification in men with clinically suspected prostate cancer.
    J Natl Cancer Inst. 2026 Feb 2:djag027. doi: 10.1093.
    

    >> Share

    
    

    
    J Nucl Med

22. MURTHY V, Kimura K, Theus L, Nguyen A, et al
    Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [(177)Lu]Lu-PSMA-617: A Single-Center Retrospective Study.
    J Nucl Med. 2025 Dec 4:jnumed.125.270916. doi: 10.2967/jnumed.125.270916.
    

    >> Share

    
    
23. HARTENBACH M, Rasul S, Grubmuller B, Kramer G, et al
    PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial.
    J Nucl Med. 2025 Nov 20:jnumed.125.270404. doi: 10.2967/jnumed.125.270404.
    

    >> Share

    
    

    
    Lancet Oncol

24. TANG C, Sherry AD, Hwang H, Farris DP, et al
    Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.
    Lancet Oncol. 2026;27:181-190.
    

    >> Share

    
    
25. SPOHN SKB, Grosu AL
    Oligometastatic prostate cancer: time to integrate metastasis-directed therapy.
    Lancet Oncol. 2026;27:139-141.
    

    >> Share

    
    

    
    Magn Reson Imaging

26. ZHANG KS, Glemser PA, Neelsen CJO, Wennmann M, et al
    Repeatability and reproducibility of maximum diameter measurements of prostate lesions on MRI with repositioning and variation of imaging sequences: A test-retest study.
    Magn Reson Imaging. 2025 Nov 27:110578. doi: 10.1016/j.mri.2025.110578.
    

    >> Share

    
    

    
    Oncogene

27. BROOKE GN, Leach DA, Culley RL, Azadova A, et al
    Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS/TLS alters androgen signalling in prostate cancer.
    Oncogene. 2026 Feb 6. doi: 10.1038/s41388-026-03682.
    

    >> Share

    
    

    
    Oncol Rep

28. SHEN P, Wang X, Yan X, Du H, et al
    High RMI1 expression is associated with cancer cell progression and poor prognosis in prostate cancer.
    Oncol Rep. 2026;55:55.
    

    >> Share

    
    

    
    PLoS One

29. ZHANG C, Yu J, Ji T, Zhao K, et al
    Loss of IL1RA promotes prostate cancer growth and metastasis by activating Akt signaling pathway.
    PLoS One. 2026;21:e0339611.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

30. TENDLER S, De Gregorio R, Balderes P, Michel AL, et al
    Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers.
    Proc Natl Acad Sci U S A. 2026;123:e2505785123.
    

    >> Share

    
    

    
    Urol Int

31. POLAT H, Sungur U, Eksi M, Guner E, et al
    The Relationship of Chronic Inflammation in Prostate Biopsies with International Society of Urological Pathology Score Upgrade after Radical Prostatectomy.
    Urol Int. 2026;110:55-61.
    

    >> Share

    
    
32. DONCK E, Fede Spicchiale C, Yang T, Bou Kheir G, et al
    Pelvic lymph node dissection during radical prostatectomy for prostate cancer: harms versus benefits.
    Urol Int. 2026 Feb 2:1-21. doi: 10.1159/000550027.
    

    >> Share

    
    

    
    Urology

33. SHACHAR E, Connor SE, Chen J, Kwan L, et al
    Authors' Reply to Editorial Comments on, "Fear of Cancer Recurrence among Uninsured and Underrepresented Men with Prostate Cancer".
    Urology. 2026 Jan 29:S0090-4295(26)00071-3. doi: 10.1016/j.urology.2026.
    

    >> Share

    
    
34. BILEN MA, Shore N, Burbage S, Rossi C, et al
    Homologous recombination repair mutations, next-generation sequencing testing, and treatment progression by race among patients with metastatic castration-sensitive prostate cancer.
    Urology. 2026 Jan 29:S0090-4295(26)00060-9. doi: 10.1016/j.urology.2026.
    

    >> Share

    
    
35. ASHOURI R, Reynolds PS, Rajavel S, Hanchate K, et al
    Development of a Prognostic Prediction Model for Clinically Significant Prostate Cancer Based on Lesion Zone and Apparent Diffusion Coefficient Value Quantification.
    Urology. 2026 Jan 28:S0090-4295(26)00061-0. doi: 10.1016/j.urology.2026.
    

    >> Share

    
    
36. HANSEN SC, Schlaepfer CH, Shane DM, Erickson BA, et al
    Measuring the Impact of Common Prostate Cancer Survivorship Conditions with Health Utilities.
    Urology. 2026 Jan 29:S0090-4295(26)00062-2. doi: 10.1016/j.urology.2026.
    

    >> Share

    
    
37. PATNAIK S, Maganty A
    Editorial Comment on "Sociodemographic Factors Associated with Tissue-Based Genomic Testing for Prostate Cancer".
    Urology. 2026 Feb 3:S0090-4295(26)00085-3. doi: 10.1016/j.urology.2026.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share